OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community.
Our Stocks to Watch tomorrow include US Canadian Minerals Inc. (OTCBB: USCN), MAP Pharmaceuticals Inc. (Nasdaq: MAPP), Sunrise Solar Corp. (OTCBB: SSLR), Select Comfort Corp. (Nasdaq: SCSS), Cytokinetics Inc. (Nasdaq: CYTK) and Hemispherx Biopharma Inc. (Amex: HEB).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
U S CANADIAN MINERALS INCORPORATED (OTCBB: USCN) "Up 800.00% on Tuesday" US Canadian Minerals Inc. is a junior mining and exploration company whose business strategy is to grow shareholder value through acquisition, exploration and exploitation of near term production precious metal properties in North and South America.
MAP PHARMACEUTICALS INCORPORATED (NASDAQ: MAPP) "Up 185.71% on Tuesday" MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. The company’s product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals. MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California.
SUNRISE SOLAR CORPORATION (OTCBB: SSLR) "Up 57.78% on Tuesday" Sunrise Solar Corporation intends to commercialize and distribute cutting edge alternative solar energy technologies and equipment. Sunrise also intends to capitalize on its institutional knowledge of emerging alternative energy technologies to develop comprehensive alternative energy plans.
SELECT COMFORT CORPORATION (NASDAQ: SCSS) "Up 25.00% on Tuesday" Founded more than 20 years ago, Select Comfort Corporation is the nation’s leading bed retailer. Based in Minneapolis, the company designs, manufactures, markets and supports a line of adjustable-firmness mattresses featuring air-chamber technology, branded the Sleep Number® bed, as well as foundations and bedding accessories. SELECT COMFORT® products are sold through its approximately 450 company-owned stores located across the United States; select bedding retailers; direct marketing operations; and online at www.sleepnumber.com.
CYTOKINETICS INCORPORATED (NASDAQ: CYTK) "Up 25.48% on Tuesday" Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company's drug candidates and potential drug candidates have arisen from research activities that are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drug candidates directed at treatments for cardiovascular disease, cancer and other diseases.
HEMISPHERX BIOPHARMA INCORPORATED (AMEX: HEB) "Up 23.26% on Tuesday" Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
About OTCPicks.com
OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release. OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
